|
Gene: SCLT1 |
Gene summary for SCLT1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SCLT1 | Gene ID | 132320 |
Gene name | sodium channel and clathrin linker 1 | |
Gene Alias | CAP-1A | |
Cytomap | 4q28.2 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | Q96NL6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
132320 | SCLT1 | CCI_1 | Human | Cervix | CC | 2.39e-07 | 9.66e-01 | 0.528 |
132320 | SCLT1 | CCI_2 | Human | Cervix | CC | 6.21e-03 | 6.61e-01 | 0.5249 |
132320 | SCLT1 | CCI_3 | Human | Cervix | CC | 6.27e-17 | 1.11e+00 | 0.516 |
132320 | SCLT1 | AEH-subject1 | Human | Endometrium | AEH | 4.68e-06 | 2.65e-01 | -0.3059 |
132320 | SCLT1 | AEH-subject2 | Human | Endometrium | AEH | 4.33e-03 | 2.05e-01 | -0.2525 |
132320 | SCLT1 | AEH-subject3 | Human | Endometrium | AEH | 5.82e-07 | 2.49e-01 | -0.2576 |
132320 | SCLT1 | AEH-subject4 | Human | Endometrium | AEH | 1.92e-09 | 4.38e-01 | -0.2657 |
132320 | SCLT1 | AEH-subject5 | Human | Endometrium | AEH | 2.29e-24 | 5.50e-01 | -0.2953 |
132320 | SCLT1 | EEC-subject1 | Human | Endometrium | EEC | 1.39e-18 | 5.71e-01 | -0.2682 |
132320 | SCLT1 | EEC-subject2 | Human | Endometrium | EEC | 6.83e-04 | 2.09e-01 | -0.2607 |
132320 | SCLT1 | EEC-subject4 | Human | Endometrium | EEC | 6.26e-08 | 3.17e-01 | -0.2571 |
132320 | SCLT1 | EEC-subject5 | Human | Endometrium | EEC | 4.15e-09 | 3.15e-01 | -0.249 |
132320 | SCLT1 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.40e-02 | -1.11e-02 | -0.1869 |
132320 | SCLT1 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 6.34e-03 | -5.13e-02 | -0.1875 |
132320 | SCLT1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 5.56e-04 | -6.85e-02 | -0.1883 |
132320 | SCLT1 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.67e-06 | -7.38e-02 | -0.1916 |
132320 | SCLT1 | LZE8T | Human | Esophagus | ESCC | 9.36e-05 | 1.86e-01 | 0.067 |
132320 | SCLT1 | LZE24T | Human | Esophagus | ESCC | 9.57e-05 | 2.00e-01 | 0.0596 |
132320 | SCLT1 | P1T-E | Human | Esophagus | ESCC | 9.46e-04 | 2.88e-01 | 0.0875 |
132320 | SCLT1 | P2T-E | Human | Esophagus | ESCC | 8.04e-29 | 5.49e-01 | 0.1177 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SCLT1 | SNV | Missense_Mutation | c.865A>T | p.Ile289Leu | p.I289L | Q96NL6 | protein_coding | deleterious(0.02) | benign(0.003) | TCGA-A2-A04N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
SCLT1 | SNV | Missense_Mutation | c.700N>C | p.Glu234Gln | p.E234Q | Q96NL6 | protein_coding | tolerated(0.1) | benign(0.132) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SCLT1 | SNV | Missense_Mutation | novel | c.1342N>C | p.Glu448Gln | p.E448Q | Q96NL6 | protein_coding | tolerated(0.53) | probably_damaging(0.935) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
SCLT1 | SNV | Missense_Mutation | rs777678930 | c.664G>A | p.Glu222Lys | p.E222K | Q96NL6 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SCLT1 | SNV | Missense_Mutation | rs764679883 | c.1205C>T | p.Ser402Leu | p.S402L | Q96NL6 | protein_coding | deleterious(0.02) | possibly_damaging(0.843) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SCLT1 | SNV | Missense_Mutation | rs11555842 | c.1954N>G | p.Gln652Glu | p.Q652E | Q96NL6 | protein_coding | tolerated(0.11) | probably_damaging(0.969) | TCGA-BH-A0BC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
SCLT1 | SNV | Missense_Mutation | c.962N>T | p.Glu321Val | p.E321V | Q96NL6 | protein_coding | tolerated(0.1) | possibly_damaging(0.731) | TCGA-C8-A135-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
SCLT1 | SNV | Missense_Mutation | c.308N>G | p.Lys103Arg | p.K103R | Q96NL6 | protein_coding | tolerated(0.32) | probably_damaging(0.994) | TCGA-E9-A1R0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
SCLT1 | deletion | Frame_Shift_Del | c.1269delN | p.Ala424GlnfsTer6 | p.A424Qfs*6 | Q96NL6 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
SCLT1 | SNV | Missense_Mutation | novel | c.1450G>A | p.Glu484Lys | p.E484K | Q96NL6 | protein_coding | deleterious(0.03) | benign(0.111) | TCGA-C5-A2LY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |